Dr. Charles (Chuck) Baum has served on Acrivon's Board since June 2023 and chairs its Compensation Committee. He has been CEO and a board member of Terremoto Biosciences since July 2024. He was the founder, President and CEO of Mirati Therapeutics from 2012 to 2021 and again from 2023 until its acquisition by Bristol Myers Squibb in January 2024, and served as its Head of Research and Development from 2021 to 2023. He serves on the board of PMV Pharmaceuticals and previously served on the boards of Poseida Therapeutics, Immunomedics, Array BioPharma and BCTG Acquisition Group. Dr. Baum received his M.D. and Ph.D. from Washington University School of Medicine and completed post-graduate training at Stanford University.